CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
(14C)-OPC-61815drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04182958
NCT04182958Phase 1Completed

A Phase I, Open-Label Trial to Assess the Mass Balance and Pharmacokinetics of a Single Intravenous Administration of (14C)-OPC-61815 to Healthy Male Japanese Subjects

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Dec 2, 2019·Updated Oct 6, 2021

In Brief

A Phase 1 clinical trial evaluating (14C)-OPC-61815 for Healthy Adult Male. Completed, enrolled 8 participants across 1 site.

Detailed Summary

* To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. * To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 * To assess the PK of total radioactivity in plasma and whole blood following a single IV infusion of (14C)-OPC-61815 * To assess the PK of OPC-61815 free form and OPC-41061 in plasma following a single IV infusion of (14C)-OPC-61815

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 2, 2019
Enrollment StartNov 25, 2019
Primary CompletionDec 19, 2019
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 6.6 years ago

Interventions

(14C)-OPC-61815drug

On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815